Exact Sciences has been working hard to expand reimbursement for its stool-based DNA colorectal cancer test since nabbing Medicare coverage last October, signing on two major private insurers earlier this year. Now the company is celebrating a decision from the Centers for Medicare and Medicaid Services that could lock in Medicare pricing for its test.
New medical devices for rectal cancer surgeries are helping patients forgo colostomies, shifting more individuals toward a new procedure that requires fewer external adjustments, according to medical experts.
Exact Sciences raked in $175 million in a public offering to dial up development of its stool-based test for colorectal cancer, giving the company a boost as it counters less-than-stellar second-quarter earnings.
Exact Sciences is building on a previous collaboration with Mayo Clinic to develop tests for the gastrointestinal tract, riding high off last year's successes and expanding its offerings beyond colorectal cancer.
Epigenomics won marketing approval in China for its next-generation colorectal cancer test, moving the company forward on its path toward global commercialization for the product and helping it compete in an increasingly competitive playing field.
Exact Sciences now has something that diagnostics companies find increasingly hard to obtain: Medicare coverage, obtained for its new cutting-edge colorectal cancer-screening test.
VolitionRx said it will pursue a CE mark application later in 2014 or early 2015, based, in part on initial positive results from a major study involving its noninvasive colorectal cancer diagnostic test panel.
Exact Sciences won FDA approval for its stool-based colorectal cancer diagnostic, charting a regulatory milestone and picking up proposed national coverage for its product along the way.
Over the long holiday weekend, Dainippon Sumitomo's shares took a beating--dropping 21% at one point, according to Bloomberg--as investors reacted to the news that BBI608 proved to be a dud in its most advanced trial for colorectal cancer.
Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.